MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options

MaxCyte

20/07/2017 18:02

RNS Number : 6906L

MaxCyte, Inc.

20 July 2017

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Maryland, USA - 20 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines, announces that it has granted, effective July 14, 2017, a total of 686,400 options of common stock in the Company ("Common Stock") to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

Option Grants to PDMRs
Doerfler, Doug
296,000
Holtz, Ron
134,800
Madhusudan, Peshwa
136,100
Thompson, J. Stark
23,900
Mandell, Art
23,900
Erck, Stan
23,900
Brooke, Will
23,900
Johnston, John
23,900
Total
686,400

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on July 14, 2017, of 242.50 pence.

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges. For more information, visit http://www.maxcyte.com/

###

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
+1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate Finance)
Duncan Monteith
Ryan McCarthy
Tom Salvesen (Corporate Broking)
+44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
+44 (0)203 709 5700
maxcyte@consilium-comms.com


1
Details of the person discharging managerial responsibilities / person closely associated
a)
Names
Doerfler, Doug
Holtz, Ron
Madhusudan, Peshwa
Thompson, J. Stark
Mandell, Art
Erck, Stan
Brooke, Will
Johnston, John
2
Reason for the notification
a)
Position/status
Doerfler, Doug - CEO and Director
Holtz, Ron - CFO and Director
Madhusudan, Peshwa - CSO
Thompson, J. Stark - Non-executive Chairman
Mandell, Art - Non-executive Director
Erck, Stan - Non-executive Director
Brooke, Will - Non-executive Director
Johnston, John - Non-executive Director
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
MaxCyte, Inc.
b)
LEI
54930053YHXULRFCU991
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Grant of Options over Shares of Common Stock
b)
Identification code
US57777K1060
c)
Nature of the transactions
Grant of Options to PDMRs
d)
Price(s) and volume(s)
Doerfler, Doug - 296,000 at an exercise price of 242.50 pence
Holtz, Ron - 134,800 at an exercise price of 242.50 pence
Madhusudan, Peshwa - 136,100 at an exercise price of 242.50 pence
Thompson, J. Stark - 23,900 at an exercise price of 242.50 pence
Mandell, Art - 23,900 at an exercise price of 242.50 pence
Erck, Stan - 23,900 at an exercise price of 242.50 pence
Brooke, Will - 23,900 at an exercise price of 242.50 pence
Johnston, John - 23,900 at an exercise price of 242.50 pence
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transactions
14 July 2017
f)
Place of the transaction
Outside a trading venue

This information is provided by RNS

The company news service from the London Stock Exchange

  END

DSHEAXXEAEEXEFF